@article{JGO21662,
author = {Homan Mohammadi and Yazan Abuodeh and William Jin and Jessica Frakes and Mark Friedman and Benjamin Biebel and Junsung Choi and Ghassan El-Haddad and Bela Kis and Jennifer Sweeney and Sarah Hoffe},
title = {Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {5},
year = {2018},
keywords = {},
abstract = {Background: The Child-Pugh (CP) class is a commonly used scoring system to measure liver function in patients with hepatocellular carcinoma (HCC). We correlate the Albumin-Bilirubin (ALBI) grading system and CP to overall survival in our HCC patients receiving radioembolization.
Methods: We retrospectively evaluated patients who received radioembolization for HCC between the years 2009–2014. We evaluated the albumin and bilirubin levels in our patients prior to receiving their first (n=124) radioembolization. The ALBI grades were calculated from these data with the formula (log10 bilirubin ×0.66) + (albumin × −0.085) and correlated to outcomes using Mantel-Cox Log analysis. These statistical comparisons were duplicated with CP classes.
Results: Median survival differences between CP class A and B and between ALBI grade 1 and 2 were 4.7 and 9.9 months, respectively. A subset of ALBI grades 1 and 2 were identified within our CP class A patients with a median survival difference of 9.9 months.
Conclusions: ALBI is a more sensitive marker of liver function than CP in the setting of mild dysfunction. Using ALBI, we identified a subset of patients that have significantly better outcomes from Y-90 radioembolization than previously identified with CP.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/21662}
}